Linked Life Data

17561988

Source:http://linkedlifedata.com/resource/pubmed/id/17561988

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17561988rdf:typepubmed:Citationlld:pubmed
pubmed-article:17561988lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0028128lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0036980lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0497247lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C1548568lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C1637379lld:lifeskim
pubmed-article:17561988lifeskim:mentionsumls-concept:C0442739lld:lifeskim
pubmed-article:17561988pubmed:issue3lld:pubmed
pubmed-article:17561988pubmed:dateCreated2008-1-16lld:pubmed
pubmed-article:17561988pubmed:abstractTextThe TRIUMPH study, recently published in Journal of the American Medical Association, was a prospective randomized placebo-controlled trial testing the hypothesis that tilarginine (a non-specific inhibitor of nitric oxide synthase), when compared with placebo, would reduce 30-day mortality by 25% in patients with myocardial infarction complicated by refractory cardiogenic shock despite successful revascularization of the infarct-related artery. Patients received an intravenous bolus of the drug followed by 5 hours of intravenous infusion of the drug or a matching placebo. Although tilarginine increased systolic blood pressure by 5 mmHg at 2 hours, no effect on mortality was observed at 30 days. There was, however, a 6% absolute increase in 30-day mortality in the tilarginine group (48%, versus 42% in the placebo). This definitive trial gave strong indications for stopping any further trial using non-specific inhibitors of nitric oxide synthase in cardiogenic shock and possibly also in any other cardiovascular area.lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:languageenglld:pubmed
pubmed-article:17561988pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:citationSubsetIMlld:pubmed
pubmed-article:17561988pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17561988pubmed:statusMEDLINElld:pubmed
pubmed-article:17561988pubmed:issn1466-609Xlld:pubmed
pubmed-article:17561988pubmed:authorpubmed-author:MebazaaAlexan...lld:pubmed
pubmed-article:17561988pubmed:authorpubmed-author:SalemRédaRlld:pubmed
pubmed-article:17561988pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17561988pubmed:volume11lld:pubmed
pubmed-article:17561988pubmed:ownerNLMlld:pubmed
pubmed-article:17561988pubmed:authorsCompleteYlld:pubmed
pubmed-article:17561988pubmed:pagination136lld:pubmed
pubmed-article:17561988pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:meshHeadingpubmed-meshheading:17561988...lld:pubmed
pubmed-article:17561988pubmed:year2007lld:pubmed
pubmed-article:17561988pubmed:articleTitleNitric oxide inhibition rapidly increases blood pressure with no change in outcome in cardiogenic shock: the TRIUMPH trial.lld:pubmed
pubmed-article:17561988pubmed:affiliationDépartement de Cardiologie, Centre Hospitalier de l'université de Montréal, 3840 rue Saint-Urbain Montréal (Québec)H2W 1T8, Canada.lld:pubmed
pubmed-article:17561988pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17561988pubmed:publicationTypeRandomized Controlled Triallld:pubmed